Golden Biotech (Taiwan)
Corporate brand
UnclaimedAn advanced drug development company focused on clinical development of new therapeutic agents for high unmet medical needs.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Golden Biotechnology Corporation (GBC) is an advanced drug development company with a team experienced in clinical development, regulatory affairs, and commercialization. It focuses on developing new therapeutic agents for patients with high unmet medical needs. Its innovative compound Antroquinonol has completed several Phase 1 and 2 studies in oncology and infectious diseases.
History
Golden Biotechnology Corporation (GBC) is an advanced drug development company. It has been committed to research and development of new therapies for more than 20 years. The company focuses on clinical development of new therapeutic agents for patients with high unmet medical needs. Its innovative compound Antroquinonol has completed a number of Phase 1 and 2 studies in oncology and infectious diseases. Recent milestones include FDA acceptance of Phase III IND application for Antroquinonol in metastatic pancreatic cancer in 2025, and IND may proceed with Phase III trial in first-line metastatic pancreatic cancer in 2026.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/golden-biotech-taiwan · Editorial policy · How profiles are compiled